ArticleParasites & vectors2018
Histopathological and immunohistochemical characterisation of hepatic granulomas in Leishmania donovani-infected BALB/c mice: a time-course study.
Article in Parasites & vectors, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- Hepatic Granulomatous Inflammation and Angiogenesis Upregulation Provoked by Acanthamoeba polyphaga Infection and Role of Quercetin-Conjugated Silver Nanoparticles.Parasite immunology · 2026Article
- Leishmania Extracellular Vesicles as a Preventive Vaccine Platform Against Leishmaniasis.Journal of extracellular vesicles · 2026Article
- Protective Effects of rLPG3 Plus Freund's Incomplete Adjuvant on Parasitism, Hepatic Function, and Immune Modulation in Experimental Visceral Leishmaniasis.ACS infectious diseases · 2026Article
- Impact of maternal visceral leishmaniasis on sex-specific immune responses and pathogenesis in offspring following homologous infections.Frontiers in immunology · 2026Article
- Effects of chitosan-titanium dioxide-Glucantime nanoassemblies onIranian journal of basic medical sciences · 2025Article
- Can letrozole be repurposed for the treatment of visceral leishmaniasis?Antimicrobial agents and chemotherapy · 2024Article
- Visceral leishmaniasis as a rare cause of granulomatous hepatitis.JPGN reports · 2024Article
- Histological findings associated with treatment response in cutaneous leishmaniasis: a clinicopathological correlation study.International journal of dermatology · 2023Article
- Immunogenicity and protective efficacy of tuzin protein as a vaccine candidate inFrontiers in immunology · 2023Article
- Wnt5A Signaling Blocks Progression of Experimental Visceral Leishmaniasis.Frontiers in immunology · 2022Article
- Effect ofArchives of Razi Institute · 2021Article
- Equine infection with Leishmania spp. in Costa Rica: Study of five cases.Veterinary medicine and science · 2021Article
- Article
- Hepatomegaly Associated with Non-Obstructive Sinusoidal Dilation in Experimental Visceral Leishmaniasis.Pathogens (Basel, Switzerland) · 2021Article
- Miltefosine enhances infectivity of a miltefosine-resistant Leishmania infantum strain by attenuating its innate immune recognition.PLoS neglected tropical diseases · 2021Article
- Potential biomarkers of immune protection in human leishmaniasis.Medical microbiology and immunology · 2021Review
- Identification of Metabolically QuiescentmBio · 2021Article
- Effects of Visceralising Leishmania on the Spleen, Liver, and Bone Marrow: A Pathophysiological Perspective.Microorganisms · 2021Review
- Granulomas in parasitic diseases: the good and the bad.Parasitology research · 2020Review
- Subcutaneous Immunization ofVaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundVisceral leishmaniasis (VL) is a neglected tropical disease (NTD), caused by the intracellular protozoan parasites Leishmania donovani and Leishmania infantum. Symptomatic VL is considered fatal when left untreated. At present, there is no effective vaccine licensed for human use and available chemotherapies have limitations. Understanding the local immune mechanisms required for the control of infection is a key factor for developing effective vaccines and therapeutics.
methodsWe have investigated the development of the typical granulomatous lesions in the liver in experimental VL over time, together with the local immune responses. BALB/c mice were infected intravenously with a dose of 2 × 10
resultsGranulomatous lesions were identified as early as 15 dpi in the livers of all infected animals. Three categories were used to classify liver granulomas (immature, mature and clear). Clear granulomas were exclusively detected from 35 dpi onwards. Kupffer cells (F4/80+) were predominant in immature granulomas, regardless of the dpi. Nonetheless, the highest expression was found 63 dpi. Positive staining for iNOS was mainly observed in the cytoplasm of fused Kupffer cells and the highest expression observed at 35 dpi. T cells (CD3+) and B cells (CD45R-B220+) were predominant in more advanced granuloma stages, probably related to the establishment of acquired immunity. Neutrophils (Ly-6G+) were predominantly observed in mature granulomas with the highest expression at 15 dpi. Neutrophils were lower in numbers compared to other cell types, particularly at later time points.
conclusionsOur results reflect the role of macrophages during the early stage of infection and the establishment of a lymphocytic response to control the infection in more advanced stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.